Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | TGM2 | P21980 | 1/20 | 0.70 |
| ▸ | KRAS | P01116 | 7/20 | 0.64 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.63 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.63 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.60 |
| ▸ | HINT1 | P49773 | 1/20 | 0.59 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18758957 | 1.00 | NT5E (0.71) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL18769144 | 1.00 | NT5E (0.71) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL21171852 | 1.00 | NT5E (0.71) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL21184245 | 0.96 | TGM2 (0.66) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL21162739 | 0.96 | TGM2 (0.66) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL18769384 | 0.95 | TGM2 (0.64) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL18769147 | 0.93 | TGM2 (0.62) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL21725246 | 0.93 | TGM2 (0.65) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL8202050 | 0.91 | NT5E (0.83) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL21184319 | 0.90 | TGM2 (0.64) | NT5ETGM2KRASFUT5IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4086269-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | ModernaTX, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3362461-B1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-10570388-B2 | Phosphate replacement MRNA cap analogs | MODERNATX, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10563195-B2 | Phosphate replacement mRNA cap analogs | MODERNATX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10428106-B2 | Phosphate replacement mRNA cap analogs | MODERNATX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190218546-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20180312535-A1 | PHOSPHATE REPLACEMENT MRNA CAP ANALOGS | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-01 | — | — | US | disclosed |
| US-20180305393-A1 | PHOSPHATE REPLACEMENT MRNA CAP ANALOGS | ARES CAPITAL CORPORATION, AS AGENT | 2018-10-25 | — | — | US | disclosed |
| US-20180291055-A1 | PHOSPHATE REPLACEMENT MRNA CAP ANALOGS | ARES CAPITAL CORPORATION, AS AGENT | 2018-10-11 | — | — | US | disclosed |
| EP-3362460-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | Modernatx, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-3362461-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | Modernatx, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066781-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066793-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428106-B2 | Phosphate replacement mRNA cap analogs | RNGTT, RNMT, CPSF6 | NT5E 522/4885TGM2 3606/4885KRAS 2691/4885 |
| US-20180291055-A1 | PHOSPHATE REPLACEMENT MRNA CAP ANALOGS | RNGTT, RNMT, CPSF6 | NT5E 522/4885TGM2 3606/4885KRAS 2691/4885 |
| US-20180305393-A1 | PHOSPHATE REPLACEMENT MRNA CAP ANALOGS | RNGTT, RNMT, CPSF6 | NT5E 522/4885TGM2 3606/4885KRAS 2691/4885 |
| US-10570388-B2 | Phosphate replacement MRNA cap analogs | RNGTT, RNMT, CPSF6 | NT5E 518/4885TGM2 3627/4885KRAS 2714/4885 |
| US-20180312535-A1 | PHOSPHATE REPLACEMENT MRNA CAP ANALOGS | RNGTT, RNMT, CPSF6 | NT5E 522/4885TGM2 3606/4885KRAS 2691/4885 |
| US-20190218546-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | RNGTT, RNMT, CPSF7 | NT5E 504/4885TGM2 3711/4885KRAS 3503/4885 |
| US-10563195-B2 | Phosphate replacement mRNA cap analogs | RNGTT, RNMT, CPSF6 | NT5E 518/4885TGM2 3627/4885KRAS 2714/4885 |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | RNGTT, RNMT, NSUN2 | NT5E 572/4885TGM2 3563/4885KRAS 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.